Cargando…

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis

Background: There is a lack of knowledge about the evolution of cerebrospinal fluid (CSF) markers in multiple sclerosis (MS) patients undergoing natalizumab treatment. Aim: We aimed to evaluate the effect of natalizumab on basic inflammatory CSF and MRI measures. Methods: Together, 411 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganapathy Subramanian, Ranjani, Horakova, Dana, Vaneckova, Manuela, Lorincz, Balazs, Krasensky, Jan, Kubala Havrdova, Eva, Uher, Tomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699923/ https://www.ncbi.nlm.nih.gov/pubmed/34943468 http://dx.doi.org/10.3390/diagnostics11122230

Ejemplares similares

Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis
por: Motyl, Jiri, et al.
Publicado: (2021)

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
por: Uher, Tomas, et al.
Publicado: (2021)

Cognitive clinico‐radiological paradox in early stages of multiple sclerosis
por: Uher, Tomas, et al.
Publicado: (2017)

Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy
por: Burgetova, Andrea, et al.
Publicado: (2022)

Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study
por: Kalincik, Tomas, et al.
Publicado: (2012)

Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis
por: Andelova, Michaela, et al.
Publicado: (2019)

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study
por: Bergsland, Niels, et al.
Publicado: (2017)

Periventricular gradient of T(1) tissue alterations in multiple sclerosis
por: Vaneckova, Manuela, et al.
Publicado: (2022)

Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis
por: Andelova, Michaela, et al.
Publicado: (2022)

MRI correlates of disability progression in patients with CIS over 48 months
por: Uher, Tomas, et al.
Publicado: (2014)

Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences
por: Uher, Tomas, et al.
Publicado: (2023)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study
por: Zivadinov, Robert, et al.
Publicado: (2013)

Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis
por: Pudlac, Adam, et al.
Publicado: (2020)

Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study
por: Ravano, Veronica, et al.
Publicado: (2021)

Reliable measurements of brain atrophy in individual patients with multiple sclerosis
por: Smeets, Dirk, et al.
Publicado: (2016)

Establishing pathological cut-offs for lateral ventricular volume expansion rates
por: Dwyer, Michael G., et al.
Publicado: (2018)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
por: Dwyer, Michael G., et al.
Publicado: (2017)

CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS
por: Burgetova, Andrea, et al.
Publicado: (2023)

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients
por: Posová, Helena, et al.
Publicado: (2017)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Real-Life Outcome in Multiple Sclerosis in the Czech Republic
por: Kobelt, Gisela, et al.
Publicado: (2019)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Cerebrospinal fluid in multiple sclerosis
por: Rammohan, Kottil W.
Publicado: (2009)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease
por: Berger, Thomas, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Multiple Sclerosis and Microbiome
por: Preiningerova, Jana Lizrova, et al.
Publicado: (2022)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Validation of the Czech Version of the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS)
por: Novotná, Klára, et al.
Publicado: (2022)

Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients – Brief Research Report
por: Moraes, Adriel S., et al.
Publicado: (2021)

Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014]
por: Stastna, Dominika, et al.
Publicado: (2023)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_14si1nb8hf9d6vaiomjlb43c4q